Brett Mellinger, MD
Urology · Garden City, NYNPI 1174586366
Payments from drug & device makers
What this record shows
This record is dominated by education: $7,550 of the $12,425 with a category attached, or 60.8%. Coloplast accounts for 68.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $6,787 and has fallen 94.1% since, to $399 in 2025.
Across 49 payments — averaging $253.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$9K
- Boston Scientific$4K
- Teleflex LLC$238
- Endo Pharmaceuticals Inc.$13
What the payments were for
- Consulting fees$9007%
- Food & beverage$3,97532%
- Education$7,55061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 14 | $8,520 |
| Boston Scientific | 32 | $3,654 |
| Teleflex LLC | 2 | $238 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$8,356
- AMS$1,146
- GENERAL ERECTILE DYSFUNCTION$511
- UroLift$238
- AMS 700$228
- GENERAL - THERAPIES$164
- GENERAL BPH$104
How this compares
$12,425 in reported general payments places this provider in the 80th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 25 | $26,701 |
| Testosterone | 78 | $20,383 |
| Testosterone Cypionate | 131 | $5,792 |
| Tadalafil | 31 | $5,401 |
| Tamsulosin Hcl | 149 | $3,175 |
| Finasteride | 134 | $2,460 |
| Solifenacin Succinate | 19 | $1,370 |
| Cefdinir | 51 | $495 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 25 | $434 |
| Dutasteride | 15 | $393 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 14 | $179 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 33 | $154 |
Paid to pharmacies, not to this prescriber.
Other urology in Garden City
- Jeffrey SchiffGarden City$198K
- Shervin BadkhshanGarden City$69K
- Joseph JamalGarden City$53K
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.